Table 5 Clinical, hormonal, and radiological findings in all patients who developed AVP deficiency after COVID-19 vaccination
Reference | Gender | Age | Vaccine | Cumulative number of doses | The time from vaccination to disease onset | Anterior pituitary hormonal disorders and co-exsisting disease | Pituitary MRI |
|---|---|---|---|---|---|---|---|
Murvelashvili et al. [12] | M | 51 | mRNA-1273; Moderna | 2nd | 3 days | Secondary adrenal insufficiency Hypothyroidism Hypogonadism | Enlargement of the pituitary gland and thickened pituitary stalk |
Ankireddypalli et al. [13] | F | 48 | BNT162b2; Pfizer-BioNTech | 1st | 2 days | Transient hypogonadism, decreased GH secretion | Thickened pituitary stalk |
Bouça et al. [14] | F | 37 | BNT162b2; Pfizer-BioNTech | 2nd | 7 days | N | Absent posterior pituitary hyperintensity on T1weighted image |
Ach et al. [15] | F | 54 | ChAdOx1 nCov-19; AstraZeneca | 1st | 3 days | N | Thickened pituitary stalk |
Ishay et al. [16] | F | 59 | BNT162b2; Pfizer-BioNTech | 1st | 8 weeks | N | Thickened pituitary stalk |
Partenope et al. [17] | M | 16 | BNT162b2; Pfizer-BioNTech | 1st | Few days | N | Thickened pituitary stalk and absent posterior pituitary hyperintensity on T1weighted image |
Matsuo et al. [18] | F | 74 | Not listed; elasomeran, Moderna | 4th | 4 weeks | Optic neuritis | Enlargement of the pituitary gland and thickened pituitary stalk |
Our case | F | 75 | Tozinameran/famtozinameran; Pfizer-BioNTech | 5th | 5 weeks | N | Thickened pituitary stalk |